Relevium to Hold Investor Call to Discuss LATAM Strategy June 28, 2019 at 1:00pm EST

Montreal, Canada – June 19, 2019 – Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”), is pleased to announce it will be holding a shareholder and investor conference call to discuss its Latin American (LATAM) strategy and the upside potential of its recently announced acquisition in Colombia.


It is estimated that Colombia is positioned to supply about 44% of the World’s market for medical cannabis and the acquisition of Lifeline Pharma SAS  (“LifeLine”) in Colombia is set to allow Biocannabix Health Corporation to target two important sources of revenues: (1) EU GMP pharma-grade extracts for export and (2) endo-nutraceutical (ENS) and oral nutritional supplements (ONS) for in-country distribution.


During this 45-minute online videoconference call, Aurelio Useche CEO of Relevium and Oscar Libreros CEO of Lifeline Pharma SAS, will provide insight into the Company’s strategy, financial objectives and discuss expected key milestones for the development of Lifeline Pharma SAS, including:


  • The expected revenue upside from the initial 20 hectares of more than $75 million through B2B exports of pharma-grade medical extracts.
  • The $100 Million opportunity in the Colombian market to introduce nutraceuticals and ONS products for pediatric and geriatric applications through pharmacies and direct to hospitals
  • The ability of Lifeline to generate positive cash flows from operations in the first 12 month of operations
  • The stages of development of the project and ability to expand quickly to 85 hectares to meet global demand
  • The importance of controlling plant genetics and the registration of 668 genetic strains with the ICA, the Instituto Colombiano Agropecuario.
  • Strategic low-cost infrastructure that allows for an estimated stage two capacity of 170,000 Kg of medical cannabis per year with an initial estimated cost of production 0.53$ per gram.
  • The strategic importance of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project.
  • Local partnerships including the International Center for Tropical Agriculture (CIAT), Hospitals, medical clinics and the Colombian Corporation for Agricultural Research (Agrosavia).



In order to attend Relevium’s LATAM Strategy Conference Call, please use the following link to pre-register your attendance. Once registered you will receive your call instructions and you will be able to add the event to your calendar.


Please Click:


About Relevium Technologies

Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as and


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


About Lifeline Pharma

Lifeline Pharma SAS is a privately owned vertically integrated agro-pharma business dedicated to scientific research, grow, extraction, production and export of medicinal grade cannabis derivatives. Incorporated in Cali, Colombia, Lifeline leverages 150 years of organic agriculture located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave, only 7 minutes away from the international airport and 10 minutes away from Cali, the third largest city in the country.


Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.


On Behalf of the Board of Directors


Aurelio Useche
President and CEO


For more information about this press release: Tel: +1.888.528.8687


Email: investors@releviumcorp.comWebsite: www.releviumtechnologies.comLike us on Facebook
Follow us on TwitterFollow us on LinkedIn


Source: Relevium Technologies Inc